Cargando…
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
SUMMARY: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen 4/B7 (CTLA-4/B7) pathways are key regulators in T-cell activation and tolerance. Nivolumab, pembrolizumab (PD-1 inhibitors), atezolizumab (PD-L1 inhibitor) and ipilimumab (...
Autores principales: | Lupi, Isabella, Brancatella, Alessandro, Cosottini, Mirco, Viola, Nicola, Lanzolla, Giulia, Sgrò, Daniele, Dalmazi, Giulia Di, Latrofa, Francesco, Caturegli, Patrizio, Marcocci, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790893/ https://www.ncbi.nlm.nih.gov/pubmed/31610523 http://dx.doi.org/10.1530/EDM-19-0102 |
Ejemplares similares
-
Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
por: Lanzolla, Giulia, et al.
Publicado: (2019) -
Autoimmune polyendocrinopathy and hypophysitis after Puumala hantavirus infection
por: Tarvainen, Marlene, et al.
Publicado: (2016) -
Xanthogranulomatous hypophysitis: a rare and often mistaken pituitary lesion
por: Gopal-Kothandapani, Jaya Sujatha, et al.
Publicado: (2015) -
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021) -
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)